Santen Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Osaka Japan (1890)

Organization Overview

First Clinical Trial
2003
NCT00136344
First Marketed Drug
1999
pemirolast (alamast)
First NDA Approval
1999
pemirolast (alamast)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SANTEN | Santen Gmbh | Santen Inc. | Santen Oy | Santen Pharmaceutical | Santen Pharmaceutical Co., Ltd. | Santen Pharmaceutical (Taiwan) Co., LTD | Santen SAS